Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab (Mabcampath) for refractory or relapsed acute lymphoblastic leukemia (CD52+)
2004-001739-53Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Nov 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in acute lymphoblastic leukemia (ALL), sponsored by GIMEMA. Started Nov 2004; status: completed.
02
Drugs
alemtuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2004-001739-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001739-53.